Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12663) 12663
Publication (1264) 1264
Newsletter (577) 577
Book Review (268) 268
Newspaper Article (149) 149
Book Chapter (98) 98
Magazine Article (83) 83
Transcript (56) 56
Trade Publication Article (20) 20
Book / eBook (17) 17
Conference Proceeding (17) 17
Dissertation (13) 13
Reference (3) 3
Web Resource (2) 2
Data Set (1) 1
Paper (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9518) 9518
index medicus (5582) 5582
protease inhibitors (4591) 4591
male (4578) 4578
female (4109) 4109
hiv infections - drug therapy (4038) 4038
adult (3438) 3438
proteases (3250) 3250
middle aged (2736) 2736
animals (2569) 2569
hiv (2367) 2367
pharmacology & pharmacy (2302) 2302
hiv protease inhibitors - adverse effects (2266) 2266
infectious diseases (2240) 2240
hiv protease inhibitors - therapeutic use (1687) 1687
drug therapy, combination (1681) 1681
immunology (1562) 1562
health aspects (1495) 1495
drug therapy (1404) 1404
antiretroviral therapy (1351) 1351
anti-hiv agents - adverse effects (1334) 1334
treatment outcome (1327) 1327
anti-hiv agents - therapeutic use (1314) 1314
research (1277) 1277
antiviral agents (1218) 1218
analysis (1209) 1209
risk factors (1206) 1206
protease inhibitors - therapeutic use (1109) 1109
aged (1095) 1095
hiv infection (1091) 1091
care and treatment (1061) 1061
hiv infections - complications (1055) 1055
protease inhibitor (1054) 1054
virology (977) 977
highly active antiretroviral therapy (976) 976
drug interactions (950) 950
viral load (946) 946
therapy (933) 933
hiv protease inhibitors - administration & dosage (901) 901
aids (900) 900
ritonavir (896) 896
proteins (854) 854
biochemistry & molecular biology (837) 837
human-immunodeficiency-virus (829) 829
mice (827) 827
human immunodeficiency virus--hiv (797) 797
antiretroviral therapy, highly active - adverse effects (790) 790
ritonavir - adverse effects (782) 782
hepatitis c (757) 757
hepatitis c virus (756) 756
microbiology (748) 748
cd4 lymphocyte count (746) 746
hiv infections - virology (742) 742
antiviral agents - therapeutic use (736) 736
protease inhibitors - adverse effects (718) 718
protease (696) 696
reverse transcriptase inhibitors - therapeutic use (689) 689
adolescent (683) 683
pharmacokinetics (668) 668
physiological aspects (668) 668
protease inhibitors - pharmacology (668) 668
antiretroviral drugs (661) 661
medicine & public health (660) 660
infection (649) 649
article (647) 647
ritonavir - therapeutic use (644) 644
hiv-1 (641) 641
hiv patients (640) 640
antiretroviral therapy, highly active (631) 631
active antiretroviral therapy (618) 618
reverse transcriptase inhibitors - adverse effects (604) 604
anti-hiv agents - administration & dosage (580) 580
medicine, general & internal (577) 577
hepatitis c, chronic - drug therapy (566) 566
medical research (566) 566
ritonavir - administration & dosage (566) 566
hiv-1 - drug effects (562) 562
gastroenterology & hepatology (554) 554
lipodystrophy (547) 547
in-vitro (542) 542
oncology (540) 540
time factors (532) 532
dose-response relationship, drug (525) 525
rats (522) 522
medicine (519) 519
apoptosis (518) 518
dosage and administration (515) 515
prospective studies (513) 513
cancer (508) 508
lopinavir (507) 507
research article (507) 507
young adult (503) 503
hiv-infected patients (502) 502
enzymes (501) 501
drug administration schedule (498) 498
expression (498) 498
clinical trials (493) 493
virus diseases (487) 487
drugs (485) 485
clinical trials as topic (481) 481
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13136) 13136
Spanish (154) 154
German (116) 116
French (98) 98
Japanese (36) 36
Russian (21) 21
Italian (16) 16
Danish (11) 11
Dutch (10) 10
Portuguese (8) 8
Polish (7) 7
Chinese (4) 4
Swedish (4) 4
Hungarian (3) 3
Hebrew (2) 2
Norwegian (2) 2
Serbian (2) 2
Turkish (2) 2
Arabic (1) 1
Croatian (1) 1
Czech (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
by Chayama, Kazuaki and Takahashi, Shoichi and Toyota, Joji and Karino, Yoshiyasu and Ikeda, Kenji and Ishikawa, Hiroki and Watanabe, Hideaki and McPhee, Fiona and Hughes, Eric and Kumada, Hiromitsu
Hepatology, ISSN 0270-9139, 03/2012, Volume 55, Issue 3, pp. 742 - 748
Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg‐IFN) and ribavirin (RBV) have limited... 
NS5A INHIBITOR | TELAPREVIR | PEGINTERFERON ALPHA-2A | BMS-650032 | BMS-790052 | ALPHA-2A PLUS RIBAVIRIN | RESISTANCE | RANDOMIZED-TRIAL | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | HCV INFECTION | Recombinant Proteins - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Diarrhea - epidemiology | Male | Diarrhea - chemically induced | Polyethylene Glycols - therapeutic use | Incidence | Hepatitis C - ethnology | Treatment Failure | Protease Inhibitors - adverse effects | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Headache - chemically induced | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Japan | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Headache - epidemiology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Aged | Viral Nonstructural Proteins - antagonists & inhibitors | Proteins | Hepatitis | Genotype & phenotype | Interferon | Infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
by Arribas, Jose R, Dr and Pialoux, Gilles, Prof and Gathe, Joseph, MD and Di Perri, Giovanni, Prof and Reynes, Jacques, Prof and Tebas, Pablo, MD and Nguyen, Thai, MD and Ebrahimi, Ramin, MS and White, Kirsten, PhD and Piontkowsky, David, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Summary Background Patients with HIV on antiretroviral therapy might benefit from regimen simplification to reduce pill burden and dosing frequency. We aimed... 
Infectious Disease | INFECTIOUS DISEASES | DISOPROXIL FUMARATE | EFAVIRENZ | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | INITIAL TREATMENT | ANTIRETROVIRAL THERAPY | INFECTED PATIENTS | SINGLE-TABLET REGIMEN | ADHERENCE | HAART | Humans | Middle Aged | Male | Thiazoles - therapeutic use | Thiazoles - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - adverse effects | Quinolones - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Protease Inhibitors - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Organophosphonates - adverse effects | Drug Therapy, Combination - methods | HIV | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Adults | Protease inhibitors | Proteases | Antiretroviral drugs | Patient satisfaction | Drug therapy | Laboratories | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Changes in bone mineral density after initiation of antiretroviral treatment with Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
by Brown, Todd T and Moser, Carlee and Currier, Judith S and Ribaudo, Heather J and Rothenberg, Jennifer and Kelesidis, Theodoros and Yang, Otto and Dubé, Michael P and Murphy, Robert L and Stein, James H and Mccomsey, Grace A
Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
by Zeuzem, Stefan and Soriano, Vincent and Asselah, Tarik and Bronowicki, Jean-Pierre and Lohse, Ansgar W and Müllhaupt, Beat and Schuchmann, Marcus and Bourlière, Marc and Buti, Maria and Roberts, Stuart K and Gane, Ed J and Stern, Jerry O and Vinisko, Richard and Kukolj, George and Gallivan, John-Paul and Böcher, Wulf-Otto and Mensa, Federico J
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 7, pp. 630 - 639
In this phase 2b study, an interferon-free regimen consisting of the combination of a protease inhibitor (faldaprevir), a nonnucleoside polymerase inhibitor... 
PROTEASE INHIBITOR | GENOTYPE-1-INFECTED SUBJECTS | ANTIVIRAL AGENTS | MEDICINE, GENERAL & INTERNAL | TELAPREVIR | C VIRUS-INFECTION | INTERFERON-FREE REGIMEN | INHIBITOR BI 207127 | RIBAVIRIN | COMBINATION | HEPATITIS-C | Enzyme Inhibitors - adverse effects | DNA-Directed RNA Polymerases - antagonists & inhibitors | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | Thiazoles - therapeutic use | Hepatitis C, Chronic - drug therapy | Oligopeptides - adverse effects | Enzyme Inhibitors - therapeutic use | Thiazoles - adverse effects | Viral Load | Oligopeptides - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Adult | Female | Hepatitis C, Chronic - genetics | Protease Inhibitors - therapeutic use | Clinical trials | Antiviral agents | Research | Hepatitis C | Drug therapy | Photosensitivity | Diarrhea | Chronic infection | Nausea | Proteinase inhibitors | Patients | Ribavirin | Hepatitis | Vomiting | Human immunodeficiency virus--HIV | Interferon | Drug dosages | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy
by Banerjee, D and Reddy, K. R
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2016, Volume 43, Issue 6, pp. 674 - 696
Summary Background Direct‐acting anti‐virals (DAAs) licensed to treat chronic HCV infection have revolutionised treatment algorithms by drastically mitigating... 
SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | ONCE-DAILY SIMEPREVIR | TREATMENT-EXPERIENCED PATIENTS | PEGYLATED INTERFERON | PHARMACOLOGY & PHARMACY | VIRUS GENOTYPE 1 | DACLATASVIR PLUS ASUNAPREVIR | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DRUG-DRUG INTERACTIONS | Isoquinolines - adverse effects | Antiviral Agents - therapeutic use | Humans | Middle Aged | Male | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Simeprevir - adverse effects | Ritonavir - adverse effects | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Sulfonamides - adverse effects | Female | Aged | Sofosbuvir - adverse effects | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Safety and security measures | Algorithms | Protease inhibitors | Proteases | Bilirubin | Biological response modifiers | Hepatitis C virus | Hepatitis C
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text New protease inhibitors for the treatment of chronic hepatitis C: A cost-effectiveness analysis
by Liu, Shan and Cipriano, Lauren E and Holodniy, Mark and Owens, Douglas K and Goldhaber-Fiebert, Jeremy D
Annals of Internal Medicine, ISSN 0003-4819, 2012, Volume 156, Issue 4, pp. 279 - 290
Background: Chronic hepatitis C virus is difficult to treat and affects approximately 3 million Americans. Protease inhibitors increase the effectiveness of... 
UNITED-STATES | ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | US POPULATION | PEGINTERFERON ALPHA-2B | GENOTYPE 1 INFECTION | QUALITY-OF-LIFE | RIBAVIRIN | VIROLOGICAL RESPONSE | HEALTH-STATE UTILITIES | Markov Chains | Ribavirin - economics | Humans | Male | Liver Cirrhosis - economics | Liver Neoplasms - etiology | Interleukins - genetics | Protease Inhibitors - adverse effects | Female | Carcinoma, Hepatocellular - etiology | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Quality-Adjusted Life Years | Liver Cirrhosis - drug therapy | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Risk Factors | Decision Support Techniques | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Genotype | Treatment Outcome | Protease Inhibitors - economics | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - economics | Disease Progression | Medication Adherence | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Cost-Benefit Analysis | Interferon-alpha - adverse effects | Antiviral Agents - economics | Hepatitis C, Chronic - genetics | Research | Protease inhibitors | Hepatitis C | Drug therapy | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Direct-acting antivirals for chronic hepatitis C
by Jakobsen, Janus C and Nielsen, Emil Eik and Feinberg, Joshua and Katakam, Kiran Kumar and Fobian, Kristina and Hauser, Goran and Poropat, Goran and Djurisic, Snezana and Weiss, Karl Heinz and Bjelakovic, Milica and Bjelakovic, Goran and Klingenberg, Sarah Louise and Liu, Jian Ping and Nikolova, Dimitrinka and Koretz, Ronald L and Gluud, Christian
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, pp. CD012143 - CD012143
Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are... 
Hepacivirus - drug effects | Nucleic Acid Synthesis Inhibitors - therapeutic use | Nucleic Acid Synthesis Inhibitors - adverse effects | Antiviral Agents - therapeutic use | Humans | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - mortality | Simeprevir - therapeutic use | Cause of Death | Safety-Based Drug Withdrawals | Simeprevir - adverse effects | Randomized Controlled Trials as Topic | Placebos - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Protease Inhibitors - therapeutic use | SUSTAINED VIROLOGICAL RESPONSE | PLUS PEGINTERFERON ALPHA-2B/RIBAVIRIN | PHASE-III TRIAL | NONNUCLEOSIDE POLYMERASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | PEGYLATED INTERFERON ALPHA-2A | HCV GENOTYPE 1 | TREATMENT-EXPERIENCED PATIENTS | NS3/4A PROTEASE INHIBITOR | TREATMENT-NAIVE PATIENTS | PATIENT-REPORTED OUTCOMES | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights